Chenghua Xia

2.5k total citations · 1 hit paper
11 papers, 1.9k citations indexed

About

Chenghua Xia is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Chenghua Xia has authored 11 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 5 papers in Pulmonary and Respiratory Medicine and 5 papers in Oncology. Recurrent topics in Chenghua Xia's work include Renal cell carcinoma treatment (3 papers), Renal and related cancers (3 papers) and Cutaneous Melanoma Detection and Management (3 papers). Chenghua Xia is often cited by papers focused on Renal cell carcinoma treatment (3 papers), Renal and related cancers (3 papers) and Cutaneous Melanoma Detection and Management (3 papers). Chenghua Xia collaborates with scholars based in United States, Canada and United Kingdom. Chenghua Xia's co-authors include Walter M. Stadler, Keith T. Flaherty, Peter J. O’Dwyer, Ronit Simantov, Eric K. Rowinsky, Mark J. Ratain, James L. Abbruzzese, Amita Patnaik, Brian Schwartz and Martin Gore and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Chenghua Xia

11 papers receiving 1.9k citations

Hit Papers

Phase II Placebo-Controlled Randomized Discontinuation Tr... 2006 2026 2012 2019 2006 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma
    2006 794 citations Mark J. Ratain, Tim Eisen et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chenghua Xia United States 10 1.2k 950 843 468 156 11 1.9k
Michael Millward Australia 25 1.1k 0.9× 1.7k 1.8× 1.1k 1.4× 331 0.7× 142 0.9× 43 2.9k
Nicoletta Brega United States 16 995 0.8× 825 0.9× 804 1.0× 301 0.6× 171 1.1× 52 2.1k
Tinya J. Abrams United States 12 936 0.8× 835 0.9× 824 1.0× 322 0.7× 135 0.9× 17 2.1k
Heike Richly Germany 20 1.1k 0.9× 1.2k 1.2× 736 0.9× 380 0.8× 326 2.1× 56 2.4k
Anthony M. D’Amelio United States 16 1.4k 1.2× 1.4k 1.5× 1.6k 1.9× 697 1.5× 459 2.9× 37 2.9k
Panos Fidias United States 25 925 0.8× 1.7k 1.8× 1.8k 2.2× 276 0.6× 139 0.9× 58 3.0k
Mariacarmela Santarpía Italy 28 1.1k 0.9× 1.3k 1.3× 1.1k 1.3× 629 1.3× 176 1.1× 118 2.4k
Marta Guix Spain 17 1.1k 0.9× 1.4k 1.5× 714 0.8× 599 1.3× 260 1.7× 43 2.5k
Irene Braña Spain 26 1.3k 1.0× 1.3k 1.3× 601 0.7× 359 0.8× 251 1.6× 137 2.6k
Oana Petrenciuc United States 16 552 0.5× 779 0.8× 1.0k 1.2× 335 0.7× 130 0.8× 36 1.6k

Countries citing papers authored by Chenghua Xia

Since Specialization
Citations

This map shows the geographic impact of Chenghua Xia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chenghua Xia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chenghua Xia more than expected).

Fields of papers citing papers by Chenghua Xia

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chenghua Xia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chenghua Xia. The network helps show where Chenghua Xia may publish in the future.

Co-authorship network of co-authors of Chenghua Xia

This figure shows the co-authorship network connecting the top 25 collaborators of Chenghua Xia. A scholar is included among the top collaborators of Chenghua Xia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chenghua Xia. Chenghua Xia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Bulat, Iurie, Kathleen N. Moore, John Chung, et al.. (2018). Phase Ib study of anti-mesothelin antibody drug conjugate anetumab ravtansine in combination with pegylated liposomal doxorubicin in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.. Journal of Clinical Oncology. 36(15_suppl). 5571–5571. 13 indexed citations
2.
Spreafico, Anna, Michael B. Sawyer, Lillian L. Siu, et al.. (2018). Effects of rifampin on the pharmacokinetics of copanlisib, a novel pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor in cancer patients.. Journal of Clinical Oncology. 36(15_suppl). e14559–e14559. 1 indexed citations
3.
Bukowski, Ronald M., Walter M. Stadler, David F. McDermott, et al.. (2010). Safety and Efficacy of Sorafenib in Elderly Patients Treated in the North American Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program. Oncology. 78(5-6). 340–347. 33 indexed citations
4.
Stadler, Walter M., Robert A. Figlin, David F. McDermott, et al.. (2010). Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer. 116(5). 1272–1280. 193 indexed citations
5.
Pacey, Simon, Mark J. Ratain, Keith T. Flaherty, et al.. (2009). Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. Investigational New Drugs. 29(3). 481–488. 40 indexed citations
6.
Hauschild, Axel, Sanjiv S. Agarwala, Uwe Trefzer, et al.. (2009). Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma. Journal of Clinical Oncology. 27(17). 2823–2830. 415 indexed citations
7.
Flaherty, Keith T., Joan H. Schiller, Lynn M. Schuchter, et al.. (2008). A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel. Clinical Cancer Research. 14(15). 4836–4842. 118 indexed citations
8.
McDermott, David F., Jeffrey A. Sosman, René González, et al.. (2008). Double-Blind Randomized Phase II Study of the Combination of Sorafenib and Dacarbazine in Patients With Advanced Melanoma: A Report From the 11715 Study Group. Journal of Clinical Oncology. 26(13). 2178–2185. 182 indexed citations
9.
Adjei, Alex A., Julian R. Molina, Sumithra J. Mandrekar, et al.. (2007). Phase I Trial of Sorafenib in Combination with Gefitinib in Patients with Refractory or Recurrent Non–Small Cell Lung Cancer. Clinical Cancer Research. 13(9). 2684–2691. 81 indexed citations
10.
Ratain, Mark J., Tim Eisen, Walter M. Stadler, et al.. (2006). Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 24(16). 2505–2512. 794 indexed citations breakdown →
11.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael Millward Breakdown of academic impact, for papers by Nicoletta Brega Breakdown of academic impact, for papers by Tinya J. Abrams Breakdown of academic impact, for papers by Heike Richly Breakdown of academic impact, for papers by Anthony M. D’Amelio Breakdown of academic impact, for papers by Panos Fidias Breakdown of academic impact, for papers by Mariacarmela Santarpía Breakdown of academic impact, for papers by Marta Guix Breakdown of academic impact, for papers by Irene Braña Breakdown of academic impact, for papers by Oana Petrenciuc
Rankless by CCL
2026